CONTINUOUS GLUCOSE MONITORING DEVICES MARKET ANALYSIS

Leading Companies

Global Continuous Glucose Monitoring Devices Market: Key Developments

In February 2023, Dario Health Corp. announced an agreement with Dexcom to integrate its CGM, into Dario's multi-chronic condition platform. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for individuals using the wearable device to benefit from Dario's highly personalized support.

In December 2022, Dexcom announced that its G7 continuous glucose monitoring (CGM) system has received FDA clearance. The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and up, is expected to launch in the U.S.

In June 2022, Ascensia Diabetes Care announced that Senseonics Holdings, Inc. has received CE Mark approval for the Eversense E3 Continuous Glucose Monitoring (CGM) System, clearing the way for its use in European Union (EU) member countries.

In January 2019, the Food and Drug Administration (FDA) approved the first implantable CGM (continuous glucose monitoring) device, called the Eversense CGM System, for people with Type 1 and Type 2 diabetes. The Eversense CGM System provides monitoring for up to three months, and it’s approved for people age 18 and older.

Global Continuous Glucose Monitoring Devices Market: Key Companies Insights

The global continuous glucose monitoring devices market is highly competitive. This is attributed to the growing prevalence of diabetes and growing geriatric population, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global continuous glucose monitoring devices market are Abbott, Medtronic, Dexcom, Inc., Novo Nordisk A/S, Ypsomed, GlySens Incorporated, and F. Hoffmann-La Roche Ltd., among others.